Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN7075 plus cemiplimab in advanced solid tumors
2022-501234-37-00Phase 2Authorised
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 7
01
Overview
Phase 2, open-label trial of dalmitamig and cemiplimab in Nonhematologic neoplasms (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 4 more. Planned start Aug 2023; status: authorised.
02
Drugs
dalmitamigcemiplimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2022-501234-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501234-37-00.